Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer (NCT06686771)

🧪 Interventions in This Study

• SBRT (RADIATION)
• First or second-line standard of care therapy (OTHER)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Metastatic disease (stage IV) detected on imaging and histologically and/or cytologically confirmed NSCLC as per the WHO Classification of Tumors and AJCC 8th Edition TNM Classification, without a driver mutation with an actionable first-line targeted therapy, for whom either ICI alone or combination ICI + chemotherapy is indicated
2. Oligoprogression on first-line ICI +/- chemotherapy systemic therapy after at least 3 cycles.
3. All sites of oligoprogression can be safely treated with SBRT or ablative radiotherapy as determined by radiation treatment preplan, including availability and tolerability of necessary technologies (e.g., active breathing control, MRLinac, fiducial insertion, etc.) and accounting for previous radiotherapy overlap. Safety must be assessed and determined by a radiation oncologist.
4. Patients with treated CNS disease who have radiologic and clinical evidence of stable brain metastases, with no evidence of cavitation or hemorrhage in the brain lesion, are eligible providing that they are asymptomatic and do not require corticosteroids (must have discontinued steroids at least 1 week prior to randomization).
5. Candidate for regulatory approved SOC first-line orsecond-line systemic therapy options.
6. Participants must be ≥ 18 years of age.
7. ECOG performance status of 0, 1 or 2.
8. Participants that received prior adjuvant/neoadjuvant/consolidation systemic therapy (including chemotherapy and ICI ) are eligible if at least 6 months have elapsed between the completion of prior therapy and start of first-line treatment for metastatic disease.
9. Participants must have recovered to ≤ grade 1 from all reversible toxicity related to prior systemic therapy. If participants experienced prior immune-mediated toxicity and have not yet re-initiated ICI therapy, please contact CCTG. Please also contact CCTG if participants have ongoing toxicity ≥ grade 1 felt to be clinically insignificant.
10. Previous surgery related to NSCLC in the curative or metastatic disease setting is permitted. Previous major surgery is permitted provided that surgery occurred at least 28 days prior to participant enrollment and that wound healing has occurred.
11. Prior external beam radiation related to NSCLC in the metastatic disease setting is permitted provided a minimum of 14 days (2 weeks) have elapsed between the last dose of radiation and date of enrollment. Patients that received prior external beam radiation therapy in the NSCLC curative disease setting (including the primary lesion) are eligible. Oligoprogressive lesions previously treated with external beam radiation are eligible as long they are clinically asymptomatic, and re-treatment is possible according to the investigator.
12. Prior conventional, non-stereotactic radiotherapy for palliative purposes is allowed, and if the palliated lesion subsequently progressed but asymptomatic not requiring immediate RT, the lesion can still be counted toward one of the five oligoprogressive lesions.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (75 Sites)

Showing the first 25 of 75 sites.

• Mayo Clinic Hospital in Arizona — Phoenix, Arizona
• City of Hope Comprehensive Cancer Center — Duarte, California
• City of Hope at Irvine Lennar — Irvine, California
• Saint Mary's Hospital and Regional Medical Center — Grand Junction, Colorado
• CTCA at Southeastern Regional Medical Center — Newnan, Georgia
• Saint Luke's Cancer Institute - Boise — Boise, Idaho
• Saint Luke's Cancer Institute - Fruitland — Fruitland, Idaho
• Saint Luke's Cancer Institute - Meridian — Meridian, Idaho
• Saint Luke's Cancer Institute - Nampa — Nampa, Idaho
• Alton Memorial Hospital — Alton, Illinois
• Northwestern University — Chicago, Illinois
• Decatur Memorial Hospital — Decatur, Illinois
• Northwestern Medicine Cancer Center Kishwaukee — DeKalb, Illinois
• Crossroads Cancer Center — Effingham, Illinois
• Northwestern Medicine Cancer Center Delnor — Geneva, Illinois
• Northwestern Medicine Glenview Outpatient Center — Glenview, Illinois
• Northwestern Medicine Grayslake Outpatient Center — Grayslake, Illinois
• Northwestern Medicine Lake Forest Hospital — Lake Forest, Illinois
• HSHS Saint Elizabeth's Hospital — O'Fallon, Illinois
• Northwestern Medicine Oak Brook — Oak Brook, Illinois
• Northwestern Medicine Orland Park — Orland Park, Illinois
• Memorial Hospital East — Shiloh, Illinois
• Northwestern Medicine Cancer Center Warrenville — Warrenville, Illinois
• UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
• Mercy Hospital — Cedar Rapids, Iowa

📞 Contact the Study Coordinator

Phone: (613) 533-6430

Email: p-ogaudreau@ctg.queensu.ca

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Non-small Cell Lung Cancer

• Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations — Birmingham, Alabama
• A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer — Anchorage, Alaska
• Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) — La Jolla, California
• PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer — Houston, Texas
• Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer — Renton, Washington
• BBO-11818 in Adult Subjects With KRAS Mutant Cancer — Los Angeles, California

Explore by condition: All Non-small Cell Lung Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.